A Phase 4 Randomized Clinical Trial of Andexanet Alfa [Andexanet Alfa for Injection] in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Andexanet alfa (Primary)
- Indications Intracranial haemorrhages
- Focus Therapeutic Use
- Sponsors Portola Pharmaceuticals
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 07 Sep 2018 Status changed from planning to not yet recruiting.
- 10 May 2018 New trial record